NFE2L2 and early-onset autosomal dominant Alzheimer disease: Activation of Nrf2 has been suggested as a viable strategy for the treatment of inflammatory neurodegenerative CNS diseases, such as multiple sclerosis, Parkinson’s disease, and Alzheimer’s disease [12,13].